Enhancing hemophilia A gene therapy by strategic F8 deletions in AAV vectors
{{output}}
Hemophilia A, caused by a deficiency in factor VIII (F8), is a promising target for gene therapy. This study aims to enhance the efficacy of adeno-associated virus serotype 8 (AAV8) vectors, specifically those encoding B-domain-deleted F8 (BDDF8), to treat the... ...
